Skip to Content

Doribax Side Effects

Generic Name: doripenem

Medically reviewed by Last updated on Aug 27, 2020.

Note: This document contains side effect information about doripenem. Some of the dosage forms listed on this page may not apply to the brand name Doribax.

For the Consumer

Applies to doripenem: intravenous powder for suspension

Side effects requiring immediate medical attention

Along with its needed effects, doripenem (the active ingredient contained in Doribax) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking doripenem:

More common

  • Bluish color
  • diarrhea
  • pain, tenderness, or swelling of the foot or leg
  • pale skin
  • troubled breathing with exertion
  • unusual bleeding or bruising
  • unusual tiredness or weakness

Less common

  • Abdominal or stomach cramps, pain, or tenderness
  • bloody urine
  • decreased frequency or amount of urine
  • fever
  • increased blood pressure
  • increased thirst
  • itching or pain of the vagina or genital area
  • loss of appetite
  • lower back or side pain
  • nausea or vomiting
  • sore mouth or tongue
  • swelling of the face, fingers, or lower legs
  • thick, white vaginal discharge with mild or no odor
  • troubled breathing
  • watery and severe diarrhea, which may also be bloody
  • weight gain
  • white patches in the mouth or on the tongue

Incidence not known

  • Blistering, peeling, or loosening of the skin
  • chills
  • cough
  • difficulty with swallowing or sore throat
  • dizziness
  • fast heartbeat
  • itching
  • joint or muscle pain
  • loss of bladder control
  • muscle spasm or jerking of extremities
  • puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
  • red skin lesions, often with a purple center
  • red, irritated eyes
  • skin rash or hives
  • sores, ulcers, or white spots in the mouth or on the lips
  • sudden loss of consciousness
  • tightness in the chest

Side effects not requiring immediate medical attention

Some side effects of doripenem may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

For Healthcare Professionals

Applies to doripenem: intravenous powder for injection


In 5 clinical trials, 1338 adult patients received this drug. The most common side effects were anemia, headache, nausea, diarrhea, rash, elevated hepatic enzymes, and phlebitis. During clinical studies, this drug was discontinued due to side effects in 4.1% of patients.[Ref]

Nervous system

Very common (10% or more): Headache (up to 16%)

Frequency not reported: Dizziness

Postmarketing reports: Seizure[Ref]


Very common (10% or more): Nausea (up to 12%), diarrhea (up to 12%)

Common (1% to 10%): Oral candidiasis

Uncommon (0.1% to 1%): Clostridium difficile colitis

Frequency not reported: Constipation, abdominal pain, dyspepsia[Ref]


Frequency not reported: Hypersensitivity reactions

Postmarketing reports: Anaphylaxis[Ref]

Serious and sometimes fatal hypersensitivity (anaphylactic) reactions have been reported with beta-lactams.[Ref]


Common (1% to 10%): Anemia

Postmarketing reports: Neutropenia, leukopenia, thrombocytopenia[Ref]


Common (1% to 10%): Phlebitis

Frequency not reported: Atrial fibrillation, atrial flutter, hypertension, hypotension[Ref]


Elevated hepatic enzymes also included ALT or AST at or below the upper limit of normal (ULN) at baseline increasing to greater than 5 times ULN at end of therapy.[Ref]

Common (1% to 10%): Elevated hepatic enzymes (includes elevated ALT, elevated AST, elevated transaminases)

Frequency not reported: Cholestasis[Ref]


The incidence of rash was higher in patients receiving doses greater than the approved dose compared to those receiving the approved dose. The rash resolved within 10 days after this drug was stopped.

Serious skin reactions have been reported with beta-lactams.[Ref]

Common (1% to 10%): Rash, pruritus

Frequency not reported: Erythema, macular/papular eruptions, bullous dermatitis, urticaria, erythema multiforme, allergic dermatitis, decubitus ulcer

Postmarketing reports: Stevens-Johnson syndrome, toxic epidermal necrolysis[Ref]


Common (1% to 10%): Vulvomycotic infection

Frequency not reported: Urinary tract infection, asymptomatic bacteriuria[Ref]


Pneumonitis has been reported when this drug was administered via inhalation.[Ref]

Frequency not reported: Pneumonitis, pneumonia, pleural effusion, dyspnea

Postmarketing reports: Interstitial pneumonia[Ref]


Postmarketing reports: Renal impairment/renal failure[Ref]


Frequency not reported: Hypokalemia[Ref]


Frequency not reported: Pyrexia, peripheral edema[Ref]


Frequency not reported: Insomnia, anxiety[Ref]


1. "Doripenem (Doribax)--a new parenteral carbapenem." Med Lett Drugs Ther 50 (2008): 5-7

2. Chastre J, Wunderink R, Prokocimer P, Lee M, Kaniga K, Friedland I "Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study." Crit Care Med 36 (2008): 1089-96

3. Cerner Multum, Inc "Malaysia product information." O 0 (2015):

4. "Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical, Raritan, NJ.

5. EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL:"

6. Cerner Multum, Inc. "Australian Product Information." O 0

7. "Doripenem (doribax)--a new parenteral carbapenem." Obstet Gynecol 111 (2008): 1206-7

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.